Exclusive pharmacy partner for Sucraid®
Date posted: April 18, 2022
Optum Frontier Therapies is excited to announce a new partnership with QOL Medical, LLC to support CSID patients being treated with Sucraid (sacrosidase)®
Congenital sucrase isomaltese deficiency (CSID) is an inherited condition that is estimated to affect 1 in 5,000 people1, and most symptoms appear when infants start eating solid food. People living with CSID are missing an enzyme in their digestive tract that breaks down and absorbs sugar, which results in stomach problems, excess gas, and diarrhea.
Sucraid oral solution is the only treatment available for sucrase deficiency that can occur in children and adults with congenital sucrase isomaltese deficiency (CSID). Sucraid can help improve the breakdown and absorption of sucrose (table sugar) from the intestine and can help relieve the gastrointestinal symptoms of CSID.
“People living with rare disease are often on long and complex journeys, and it is critical to simplify their access to care and expert support,” said Natasha Mayfield, Vice President and General Manager, Optum Frontier Therapies. “As a clinical partner, we are honored to be chosen by QOL Medical to deliver this important therapy to patients living with CSID.”
Learn more and access enrollment forms here.